BioMarin Pharmaceutical Inc

BMRN is consolidating within its Stage 2 advance after a blow-off peak, maintaining a medium-term bullish bias above the rising 50-day and 200-day SMAs. Short-term momentum is neutral with 9- and 20-day EMAs flat and RSI near mid-range, offering no immediate entry edge. A pullback to the 50-day SMA (around $63) or the lower end of the recent $64–$68 range would provide a lower-risk opportunity. Stalk for a test of support before initiating longs.

• ↑Q2 2026 revenue $989.7M (+20% YoY), non-GAAP operating margin 36.4%.
• ↑Raises full-year 2026 sales guidance to $3.88–$3.93B on strong product demand.
• ↓Acquisition financing adds ~$200M annual interest expense, pressuring earnings.